Bibliography
Found 40 results
Filters: Author is Clifford, David B [Clear All Filters]
White matter damage, neuroinflammation, and neuronal integrity in HAND. J Neurovirol. 2019 ;25(1):32-41.
Use of Neuroimaging to Inform Optimal Neurocognitive Criteria for Detecting HIV-Associated Brain Abnormalities. J Int Neuropsychol Soc. 2020 ;26(2):147-162.
Therapeutic amprenavir concentrations in cerebrospinal fluid. Antimicrob Agents Chemother. 2012 ;56(4):1985-9.
Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS. 2009 ;23(17):2317-22.
. Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy. J Infect Dis. 2017 ;215(1):105-113.
Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIV. Ann Clin Transl Neurol. 2020 ;7(7):1166-1173.
. Predictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy. Pain. 2015 ;156(4):731-739.
Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study. J Neurovirol. 2016 ;22(4):479-87.
Peripheral inflammation and depressed mood independently predict neurocognitive worsening over 12 years. Brain Behav Immun Health. 2022 ;21:100437.
Neuropathic pain correlates with worsening cognition in people with human immunodeficiency virus. Brain. 2022 ;145(6):2206-2213.
. Neurocognitive SuperAging in Older Adults Living With HIV: Demographic, Neuromedical and Everyday Functioning Correlates. J Int Neuropsychol Soc. 2019 ;25(5):507-519.
Neurocognitive impact of substance use in HIV infection. J Acquir Immune Defic Syndr. 2011 ;58(2):154-62.
Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis. 2015 ;60(3):473-80.
Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. J Neurovirol. 2012 ;18(6):511-20.
Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection. Clin Infect Dis. 2015 ;61(9):1476-84.
Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration. AIDS. 2012 ;26(7):890-3.
Lower CSF Aβ is Associated with HAND in HIV-Infected Adults with a Family History of Dementia. Curr HIV Res. 2016 ;14(4):324-30.
Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr. 2012 ;59(4):376-81.
Low atazanavir concentrations in cerebrospinal fluid. AIDS. 2009 ;23(1):83-7.
Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol. 2016 ;22(2):170-8.
Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol. 2008 ;64(5):566-72.
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011 ;17(1):3-16.
Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment. Virology. 2012 ;433(2):498-505.